Argos Therapeutics Names Richard Katz New CFO

Argos Therapeutics (NASDAQ: [[ticker:ARGS]]) has appointed Richard Katz the Durham, NC-based immune-oncology company’s new CFO. Katz was most recently CFO of Viamet Pharmaceuticals, also based in Durham. Previous roles include serving as CFO of Durham-based Icagen, and working as an executive in Goldman, Sachs & Company’s (NYSE: [[ticker:GS]]) healthcare group.

Katz holds a medical degree from Stanford and an MBA from Harvard. Argos is currently in late-stage clinical trials on its experimental kidney cancer treatment.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.